AllSight
Companies · KOD · Biological Products, (No Diagnostic Substances)

Kodiak Sciences Inc. (KOD)

Kodiak Sciences Inc. (KOD) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Kodiak Sciences Inc. (KOD) stock — financials & valuation

Key numbers for Kodiak Sciences Inc. (KOD): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 33/100 — a percentile rank of Kodiak Sciences Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$6.2B
EV / EBITDA-26.5×
Return on equity-396.1%
ROIC380.2%
Debt / equity0.0×
Dividend yield0.0%

Is Kodiak Sciences Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Kodiak Sciences Inc.’s own financial statements and shown as context, never as advice.

Sep 28, 2026Above the bar
Kodiak’s DAYBREAK win clears both endpoints, with Zenkuda showing 24-week durability
Aug 13, 2026Miss
The quarter missed, but Kodiak’s real test still arrives in September
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact